Article ; Online: Biomarkers and treatments for mood disorders encompassing the neurosteroid and endocannabinoid systems.
2023 Volume 35, Issue 2, Page(s) e13226
Abstract: Mood disorders, including major depressive disorder, postpartum depression, post-traumatic stress disorder and suicidality are highly prevalent, associated with a significant economic burden, and remain poorly diagnosed and poorly treated psychiatric ... ...
| Abstract | Mood disorders, including major depressive disorder, postpartum depression, post-traumatic stress disorder and suicidality are highly prevalent, associated with a significant economic burden, and remain poorly diagnosed and poorly treated psychiatric conditions. In part, this may result from the lack of biomarkers that can guide precision medicine with individualized treatments for millions of individuals who suffer these debilitating conditions worldwide. While several biomarker candidates have been proposed for mood disorders, none has been implemented in clinical practice and the treatment still relies in the prescription of selective serotonin reuptake inhibitors that shows mixed efficacy and significant side effects. Both neurosteroid biosynthesis and the endocannabinoid system have recently provided evidence for pharmacological targets to improve mood symptoms and the neuroactive steroid allopregnanolone has recently been approved by the USA Food and Drug Administration for the treatment of post-partum depression. Clinical studies also show efficacy for the management of major depression and more studies are being conducted to study efficacy in post-traumatic stress disorder. Likewise, the endocannabinoid-like modulator, N-palmioyl ethanolamide (PEA) has shown efficacy in the treatment of major depression and bipolar disorder. While these new agents are coming forward in the field of neuropsychopharmacology as a new generation of fast-acting antidepressants, the hypothesis of whether their deficits underlying mood disorders could constitute valid predictive biomarkers to facilitate diagnosis and treatment of these conditions is under consideration. |
|---|---|
| MeSH term(s) | Female ; Humans ; Mood Disorders/diagnosis ; Mood Disorders/drug therapy ; Neurosteroids/therapeutic use ; Endocannabinoids ; Depressive Disorder, Major/diagnosis ; Depressive Disorder, Major/drug therapy ; Depression, Postpartum ; Biomarkers |
| Chemical Substances | Neurosteroids ; Endocannabinoids ; Biomarkers |
| Language | English |
| Publishing date | 2023-01-10 |
| Publishing country | United States |
| Document type | Journal Article ; Review |
| ZDB-ID | 1007517-3 |
| ISSN | 1365-2826 ; 0953-8194 |
| ISSN (online) | 1365-2826 |
| ISSN | 0953-8194 |
| DOI | 10.1111/jne.13226 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 2634: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.